This was reported in a press release from the Korean regulator.

"The Food and Drug Administration will carefully examine the safety and efficacy of the preclinical data provided," the statement said.

On August 2, Russia agreed on the maximum selling price of 50 doses of the KoviVac vaccine in the amount of 21.65 thousand rubles (433 rubles per dose).

The third Russian vaccine against COVID-19, called KoviVac, was registered in February 2021.

The drug was created by the Chumakov Center of the Russian Academy of Sciences; in the course of clinical trials, it showed safety and efficacy.